secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001193125-23-292551
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC-533 Phase 1 shows clinical activity in multiple myeloma; company to seek partner, extends cash runway to 2026
--------------------------------------------------------------------------------

- As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.
- No DLTs, dose reductions, or serious TRAEs; only Grade 1-2 TRAEs observed.
- Confirmed minor response in a penta-refractory patient who had progressed on anti-BCMA bispecific.
- Dose-dependent immune activation (CD8+ T cells, NK cells) at ≥1200 mg; soluble BCMA reductions at 1600 mg.
- Company to complete ORIC-533 dose escalation in Q1 2024 then seek partner; focus on ORIC-114 and ORIC-944.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/0001193125-23-292551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312523292551/d629143d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer